CIHR IRSC
Canadian Institutes of Health Research | Instituts de recherche en santé du Canada

Canadian Common CV commun canadien

Protected when completed

Date Submitted: 2025-10-01 02:17:26
Confirmation Number: 1995090
Template: CIHR Biosketch

Dr. William Lockwood

Correspondence language: English
Sex: Male
Date of Birth: 10/21
Canadian Residency Status: Canadian Citizen
Country of Citizenship: Canada

Contact Information

The primary information is denoted by (*)

Address

Primary Affiliation (*)

BC Cancer
Department of Basic and Translational Research
Room 10.113, 675 W.10th Ave.
Vancouver British Columbia V5Z 1L3
Canada

Telephone

Laboratory (*)	604-675-8264

Email

Work (*)	wlockwood@bccrc.ca

Website

Corporate	https://www.bccrc.ca/dept/io/people/william-lockwood

CIHR IRSC
Canadian Institutes of Health Research | Instituts de recherche en santé du Canada

Canadian Common CV commun canadien

Protected when completed

Dr. William Lockwood

Degrees

2010/11 - 2014/5	Post-doctorate, Cancer Biology and Genetics (Supervisor: Harold Varmus), National Institutes of Health Degree Status: Completed
2009/10 - 2010/11	Post-doctorate, Cancer Biology and Genetics (Supervisor: Harold Varmus), Memorial Sloan-Kettering Cancer Center Degree Status: Completed
2004/9 - 2009/9	Doctorate, Doctor of Philosphy (Supervisor: Wan Lam), University of British Columbia Degree Status: Completed
2000/9 - 2004/4	Bachelor's, Bachelor's of Science, University of British Columbia Degree Status: Completed

Credentials

2024/1	Member - Basic and Translational Science Committee (Elected), International Association for the Study of Lung Cancer
2023/1	Member - Scientific Advisory Board, Lung Cancer Research Foundation
2010/1	Associate Editor, BMC Medical Genomics
2005/1	Associate Member, American Association for Cancer Research
2005/1	Member, International Association for the Study of Lung Cancer

Recognitions

2023/8	Outstanding Academic Performance (OAP) for 2022 & 2023 Academic Years, Department of Pathology and Laboratory Medicine, Faculty of Medicine University of British Columbia
2023/6	Excellence in Research and Discovery Award (Mid/Established Investigators), Department of Pathology and Laboratory Medicine, Faculty of Medicine University of British Columbia
2020/5	Outstanding reviewer recognition for exemplary contribution to peer review during the fall 2019 Project Grant competition Canadian Institutes of Health Research
2019/5	Excellence in Research and Discovery Award (Early Career) University of British Columbia
2016/4 - 2021/4	CIHR New Investigator Salary Award Canadian Institutes of Health Research

Employment

2025/4	Director Graduate Studies, Pathology and Laboratory Medicine, Faculty of Medicine, University of British Columbia
2024/7	Professor Pathology and Laboratory Medicine, Faculty of Medicine, University of British Columbia
2024/7	Distinguished Scientist Basic and Translational Research, BC Cancer Research Institute, BC Cancer, part of the Provincial Health Services Authority
2019/7 - 2024/6	Associate Professor Pathology & Laboratory Medicine, Medicine, University of British Columbia
2019/7 - 2024/6	Senior Scientist Integrative Oncology, BC Cancer Research Centre, BC Cancer, part of the Provincial Health Services Authority
2014/8 - 2019/6	Assistant Professor Pathology and Laboratory Medicine, Medicine, University of British Columbia
2014/5 - 2019/6	Scientist Integrative Oncology, BC Cancer Research Centre, BC Cancer, part of the Provincial Health Services Authority
2010/11 - 2014/4	Postdoctoral Fellow (Supervisor: Harold Varmus) National Human Genome Research Institute, Cancer Genetics Branch, National Institutes of Health
2009/10 - 2010/11	Postdoctoral Fellow (Supervisor: Harold Varmus) Cancer Biology and Genetics, Sloan-Kettering Institute, Memorial Sloan Kettering Cancer Center
2004/9 - 2009/9	Graduate Student (Supervisor: Wan Lam) Cancer Genetics and Developmental Biology, BC Cancer Research Centre, BC Cancer Agency
2004/4 - 2004/9	Laboratory Technician B.C. Cancer Research Centre

Affiliations

The primary affiliation is denoted by (*)

(*) 2024/7	Professor, Pathology and Laboratory Medicine, University of British Columbia

Research Funding History

Awarded [n=13]

2025/9 - 2027/8 Principal Applicant	Targeting epigenetic mechanisms driving lineage transformation and therapy resistance in lung adenocarcinoma **Funding Sources:** Cancer Research Society (The) Operating Grant Total Funding - 135,000 Funding Competitive?: Yes
2023/7 - 2027/6	The Environment and Lung Cancer

Principal Applicant

Funding Sources:
Terry Fox Research Institute (TFRI)
New Frontiers Program Project Grants (Team Grant)
Total Funding - 2,400,000
Funding Competitive?: Yes

Co-applicant : Stephen Lam

2021/10 - 2027/3
Principal Applicant

Understanding the effects of ERK hyperactivation in cancer: implications for therapy

Funding Sources:
Canadian Institutes of Health Research (CIHR)
Project Grant
Total Funding - 956,250
Funding Competitive?: Yes

Co-applicant : Artem Cherkasov; Gregg Morin; Kelsie Thu

2021/7 - 2026/7
Principal Applicant

PRO-Lung: Prevention and Research to Improve Outcomes for Lung Cancer, Platform II: Biology and Preclinical Therapeutics. (Capacity building initiative for the BC Cancer Lung program, mainly for faculty recruitment, infrastructure and research)

Funding Sources:
BC Cancer Foundation (Canada)
Pro-Lung Program
Total Funding - 2,940,000
Funding Competitive?: Yes

Principal Applicant : Wan Lam

2023/9 - 2025/8
Principal Applicant

ILK as a mediator of drug tolerant persister cell survival and target for combination therapy in EGFR mutant lung adenocarcinoma

Funding Sources:
Cancer Research Society (The)
Operating Grant
Total Funding - 125,000
Funding Competitive?: Yes

Co-applicant : Kevin Bennewith

2023/3 - 2024/2
Principal Applicant

SNF2 Histone Linker PHD RING Helicase as a novel tumor suppressor gene and risk factor in lung adenocarcinoma development

Funding Sources:
Canadian Institutes of Health Research (CIHR)
Priority Announcement: Cancer Research
Total Funding - 100,000
Funding Competitive?: Yes

2022/2 - 2024/2
Principal Applicant

Defining mechanisms of lineage transformation in lung adenocarcinoma to combat resistance to targeted therapies

Funding Sources:
British Columbia Lung Association
National Grant Review (NGR)/Grant-in-Aid (GIA) Awards Program
Total Funding - 50,000
Funding Competitive?: Yes

2021/9 - 2023/8
Principal Applicant

Managing EGFR inhibitor resistance in lung adenocarcinoma through drug holiday induced hyperactivation of oncogenic pathways

Funding Sources:

Cancer Research Society (The)
Operating Grant
Total Funding - 120,000
Funding Competitive?: Yes

2020/4 - 2023/3
Principal Applicant

The effects of smoking marijuana on lung cancer development: implications for screening and early detection

Funding Sources:
Canadian Institutes of Health Research (CIHR)
Project Grant
Total Funding - 688,500
Funding Competitive?: Yes

Co-investigator : Peter Stirling

2020/12 - 2022/11
Principal Applicant

SNF2 Histone Linker PHD RING Helicase as a novel tumor suppressor gene and risk factor in lung adenocarcinoma development

Funding Sources:
Lung Cancer Research Foundation
Pilot Grant
Total Funding - 150,000
Funding Competitive?: Yes

2019/10 - 2021/9
Principal Applicant

Defining mechanisms of lineage transformation in lung adenocarcinoma to combat resistance to targeted therapies

Funding Sources:
British Columbia Lung Association
Project Grant
Total Funding - 50,000
Funding Competitive?: Yes

Co-investigator : Yusuke Inoue

2016/7 - 2021/7
Principal Applicant

Developing agonistic therapeutic strategies for lung cancer based on synthetic lethal oncogene interactions

Funding Sources:
Canadian Institutes of Health Research (CIHR)
Project Scheme
Total Funding - 764,500
Funding Competitive?: Yes

Co-investigator : Gregg Morin; Sidong Huang

2016/4 - 2021/4
Principal Applicant

Integrating clinical, functional and chemical genomics to understand lung cancer biology (Salary Award)

Funding Sources:
Canadian Institutes of Health Research (CIHR)
New Investigator Salary Award
Total Funding - 300,000
Funding Competitive?: Yes

Publications

Journal Articles

1. 95 total publications from 2006-present. 88 published/accepted articles + 4 books/chapters + 3 submitted/in revision. 14 first (FA), 22 senior (SA) and 31 corresponding authorships. 7209 total citations, H-index = 47 (Google Scholar, 09/08/2025). (2026). https://scholar.google.com/citations?user=He7XywkAAAAJ&hl=. ..: ..
   Published

2. Okun SA , Lu D , Sew K , Subramaniam A , LOCKWOOD. (2025). MET Activation in Lung Cancer and Response to Targeted Therapies. Cancers. 17(2): 281.
   Published
   Refereed?: Yes

3. Wang P , Hughesman C, Yip S, LOCKWOOD WW , Sun S. (2025). Brief Report: Real-world treatment patterns and clinical outcomes for patients with advanced ALK rearranged non-small cell lung cancer (NSCLC) in British Columbia. JTO Clinical and Research Reports. 6(4): 100697.
   Published
   Refereed?: Yes

4. Vojnic M, Febres-Aldana CA, Oditsov I, Zhang T, Beach CZ,Lu D , Mattar MS, Gazzo A, Gili L, Harshan M, Ameri A, Machnicki S, Xiao X, LOCKWOOD WW, Zhou X, Yao Q, Pujadas E, Drilon A, Rekhtman N, Arcilla M, Shah N, Liu Z, Yang S, Davare MA, Ladanyi M, Somwar R. (2025). Pan-cancer analysis of oncogenic MET fusions reveals distinct pathogenomic subsets and sensitivity to MET-targeted therapy. Cancer Discovery. Epub ahead of print: Epub ahead of print.
   Published
   Refereed?: Yes

5. Shi R , Farnsworth DA , Febres-Aldana CA , Chow JLM , Sheena R , Atwal T , Gomez Marti JL , Li S , Thomas KN , Lee CM , Awrey SJ , McDonald PC , Somwar R , Dedhar S , Ladanyi M , Bennewith KL , LOCKWOOD WW. (2025). Drug tolerance and persistence to EGFR inhibitor treatment are mediated by an ILK-SFK-YAP signaling axis in lung adenocarcinoma. Oncogene. Epub ahead of print: 1-19.
   Published
   Refereed?: Yes

6. Mascaux C , Sen T , Sanchez-Cespedes M , Ortiz-Cuaran S , Bossé Y , Dammeijer F , Cavic M , Barr MP , Arulananda S , Armisen R , Berger AH , Bianchi F , Carbone DP , Cerciello F , LOCKWOOD WW , Mitsudomi T , Ohara S , Politi K , Qin S , Roisman LC , Samstein R , Skoulidis F , Tan AC , Thomas A , Zhang J , Wynes MW , John T , Tsao MS , IASLC Basic and Translational Science Committee. (2025). Advances in Lung Cancer Basic and Translational Research in 2025 - Overview and Perspectives Focusing on NSCLC. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. S1556-0864(25): 00754-3.
   Published
   Refereed?: Yes

7. Luu JK, Johnson FD, Jajarmi J, Sihota T, Shi R, Lu L, Farnsworth D, Spencer-Miko S, Negri GL, Morin G, LOCKWOOD WW. (2024). Characterizing the secretome of EGFR mutant lung adenocarcinoma. Frontiers in Oncology. 13: 1286821.
   Published
   Refereed?: Yes

8. Nagelberg A, Sihota T , Chuang YC, Shi R, Chow JLM, English J, MacAulay C, Lam S, Lam W, LOCKWOOD WW. (2024). Integrative genomics identifies SHPRH as a tumor suppressor gene in lung adenocarcinoma that regulates DNA damage response. British Journal of Cancer. 131: 534–550.
   Published
   Refereed?: Yes, Open Access?: Yes

9. Odintsov I, Makarem M, Nishino M, Bachert SE, Zhang T, LoPiccolo J, Paweletz CP, Gokhale PC, Ivanova E, Saldanha A, Rudin CM, LOCKWOOD WW, Ladanyi M, Somwar R, Jänne PA, Sholl LM. (2024). Prevalence and Therapeutic Targeting of High-Level ERBB2 Amplification in NSCLC. Journal of Thoracic Oncology. 19(5): 732-748.
Published
Refereed?: Yes

10. Trejo Vazquez JA, Towle R, Farnsworth DA , Sarafan M, LOCKWOOD WW , Garnis C. (2024). Extracellular Vesicles from Lung Adenocarcinoma Cells Induce Activation of Different Cancer-Associated Fibroblast Subtypes. Biomedicines. 12(11): 2523.
Published
Refereed?: Yes

11. Wang P, Ng R, Lam S, LOCKWOOD WW. (2024). Uncovering molecular features driving lung adenocarcinoma heterogeneity in patients who formerly smoked. Journal of Translational Medicine. 22(1): 634.
Published
Refereed?: Yes

12. Johnson FD, Hughes CS, Liu A, LOCKWOOD WW*, Morin GB* (*Co-Senior Author). (2023). Tandem mass tag-based thermal proteome profiling for the discovery of drug-protein interactions in cancer cells. STAR Protocols. 4(1): 102012.
Published
Refereed?: Yes

13. Sathiyaseelan P, Chittaranjan S, Kalloger S, Chan J, Go N, Jardon M, Ho C, Hui T, Xu J, Chow C, Gao D, Johnson F, LOCKWOOD WW, Morin G, Renouf, Schaeffer D, Gorski S. (2023). ATG4B and ATG4A loss result in two-stage cell cycle defects in pancreatic cancer cells. Journal of Cell Science. 136(19): jcs260644.
Published
Refereed?: Yes

14. Vega AA, Marshall EA, Noonan AJC, Filho FSL, Yang J, Stewart GL, Johnson FD, Vucic EA, Pewarchuk ME, Shah PP, Clem BF, Nislow C, Lam S, LOCKWOOD WW, Hallam SJ, Leung JM, Beverly LJ, Lam WL. (2023). Methionine-producing tumor micro(be) environment fuels growth of solid tumors. Cell Oncol (Dordr). 46(6): 1659-1673.
Published
Refereed?: Yes

15. Melese ES, Franks SE, Roberts ME, Hamer M, Rossi FMV, Williams M, Cederberg RA, Luu J, Harbourne BT, Shokoohi A, Ho C, Lam V, Krystal G, LOCKWOOD WW*, Bennewith KL*, Abraham N* (*co-senior authors). (2023). Longitudinal alterations in immune responses during immune checkpoint inhibitor treatment of stage IV non-small cell lung cancer patients. Molecular Oncology. (submitted): (submitted).
Submitted
Refereed?: Yes

16. Sathiyaseelan P , Chittaranjan S , Kalloger SE , Chan J , Go NE , Jardon MA , Ho CJ , Hui T , Xu J , Chow C , Gao D , Johnson FD , LOCKWOOD WW , Morin GB , Renouf DJ , Schaeffer DF , Gorski SM. (2023). Loss of ATG4B and ATG4A results in two-stage cell cycle defects in pancreatic ductal adenocarcinoma cells.Journal of cell science. 136(19): jcs260644.
Published
Refereed?: Yes

17. Elkrief A, Odintsov I, Markov V, Caeser R, Sobczuk P, Tischfield SE, Bhanot U, Vanderbilt CM, Cheng E, Drilon A, Riely GJ, LOCKWOOD WW, de Stanchina E, Tirunagaru VG, Doebele RC, Quintanal-Villalonga Á, Rudin CM, Somwar R, Ladanyi M. (2023). Combination therapy with MDM2 and MEK inhibitors is effective in patient-derived models of lung adenocarcinoma with concurrent oncogenic drivers and MDM2 amplification. Journal of Thoracic Oncology. 18(9): 1165-1183.
Published
Refereed?: Yes

18. Cohn DE, Forder A, Marshall EA, Vucic EA, Stewart GL, Noureddine K, LOCKWOOD WW, MacAulay CE, Guillaud M, Lam WL. (2023). Delineating spatial cell-cell interactions in the solid tumor microenvironment through the lens of highly multiplexed imaging. Frontiers in Immunology. 14: 1275890.
Published
Refereed?: Yes

19. Melese ES, Franks SE, Cederberg RA, Sheikh A, Lu J, Seo JH, Goodyear T, Morris KA, Milne K, Nelson B, LOCKWOOD WW, Bennewith KL, Abraham N. (2023). CD4+ Tissue Resident Memory Cells are elevated in Oncogene Driven models of Lung Adenocarcinoma. Frontiers in Immunology. (submitted): (submitted).
Submitted
Refereed?: Yes

20. Wang P, Sun S, Lam S, LOCKWOOD WW. (2023). New insights into the biology and development of lung cancer in never smokers - implications for early detection and treatment. Journal of Translational Medicine. 21(1): 585.
Published
Refereed?: Yes

21. Lu D, Nagelberg A, Chow J, Chen YT, Michalchuk Q, Somwar R, LOCKWOOD WW. (2022). MET exon 14 splice-site mutations preferentially activate KRAS signaling to drive tumorigenesis. Cancers. 14(6): 1378.
Published
Refereed?: Yes

22. Farnsworth D, Inoue Y, Johnson F, de Rappard-Yuswack G, Somwar R, Ladanyi M, Unni AM, LOCKWOOD WW. (2022). MEK inhibitor resistance in lung cancer is associated with addiction to sustained ERK suppression. NPJ Precision Oncology. 6(1): 88.
Published
Refereed?: Yes

23. Johnson F, Ferrarone J, Liu A,Brandstädter C, Munuganti R, Farnsworth D, Lu D, Luu J, Sihota T, Jansen S, Nagelberg A, Shi R, Forcina GC, Zhang X, Cheng GSW, Spencer Miko SE;de Rappard- Yuswack G , Sorensen PH, Dixon SJ, Guha U, Becker K, Djaballah H, Somwar R, Varmus H, Morin GB, LOCKWOOD WW. (2022). Characterization of a small molecule inhibitor of disulfide reductases that induces oxidative stress and lethality in lung cancer cells. Cell Reports. 38(6): 110343.
Published
Refereed?: Yes

24. Inoue Y, Nikolic A, Farnsworth D, Liu A, Ladanyi M, Somwar R, Gallo M, LOCKWOOD WW. (2021). Extracellular signal-regulated kinase mediates chromatin rewiring and lineage transformation in lung cancer. eLife. 10: e66524.
Published
Refereed?: Yes

25. Melese ES, Franks E, Cederberg RA, Harbourne BT, Shi R, Wadsworth BJ, Collier JL, Halvorsen EC, Johnson F, Luu J , Oh MH, Lam V, Krystal G, Hoover SB, Raffeld M, Simpson RM, Unni AM, Lam WL, Lam S, Abraham N, Bennewith KL*, LOCKWOOD WW* (*co-senior author). (2021). CCL5 production in lung cancer cell leads to an altered immune microenvironment and promotes tumor development. OncoImmunology. 11(1): 2010905.
Published
Refereed?: Yes

26. Calder J , Nagelberg A , Luu J , Lu D , LOCKWOOD WW. (2021). Resistance to BET inhibitors in lung adenocarcinoma is mediated by casein kinase phosphorylation of BRD4. Oncogenesis. 10(3): 27.
Published
Refereed?: Yes

27. Farnsworth DA, Chen YT, de Rappard Yuswack G, LOCKWOOD WW. (2021). Emerging Molecular Dependencies of Mutant EGFR Driven Non-Small Cell Lung Cancer. Cells. 10(12): 3553.
Published
Refereed?: Yes

28. Turgu B , Zhang F , El-Naggar A , Negri GL , Kogler M , Tortola L , Johnson F , Ng T , Li A , Yapp D , LOCKWOOD W , Martinez D , Maris JM , Daugaard M , Penninger JM , Hughes CS , Sorensen PH. (2021). HACE1 blocks $\mathrm{HIF1}\alpha$ accumulation under hypoxia in a RAC1 dependent manner. Oncogene. 40(11): 1988-2001.
Published
Refereed?: Yes

29. Xue Y , Morris J, Yang K , Johnson F, Fu Z, Zhu X, Witkowski L , Yasmeen A , Coatham M, Golenar T , Morin G, Monast A, Pilon V, Fiset P, Jung S, Gonzalez A, Camilleri-Broet S, Fu L , Postovit LM, Spicer J, Gotlieb W, Guiot MC, LOCKWOOD WW, Park M, Foulkes WF, Prudent J, Huang S. (2021). SMARCA4/2 loss inhibits chemotherapy-induced apoptosis by restricting IP3R3-mediated Ca2+ flux to mitochondria. Nature Communications. 12(1): 5404.
Published
Refereed?: Yes

30. Smith HW , Yang L , Ling C , Walsh A , Martinez VD , Boucher J , Zuo D , Sokol ES , Pavlick DC , Frampton GM , Chmielecki J , Jones LM , Roux PP , LOCKWOOD WW , Muller WJ. (2020). An ErbB2 splice variant lacking exon 16 drives lung carcinoma. Proceedings of the National Academy of Sciences of the United States of America. 117(33): 20139-20148.
Published
Refereed?: Yes

31. Liu H , Xue YC, Deng H, Mohamud Y, Ng CS, Chu A, Lim CJ, LOCKWOOD WW, Jia WWG, Luo H. (2020). microRNA modification of Coxsackievirus B3 decreases its cardiotoxicity, while retaining oncolytic potency against lung cancer. Molecular Therapy Oncolytics. 16: 207-218.
Published
Refereed?: Yes

32. Starrett JH, Guernet AA, Cuomo ME, Poels KE, van Alderwerelt van Rosenburgh IK, Nagelberg A, Farnsworth D, Price KS, Khan H, Ashtekar KD, Gaefele M, Ayeni D, Stewart TF, Kuhlmann A, Kaech S, Unni AM, Homer R, LOCKWOOD WW, Michor F, Goldberg SB, Lemmon MA, Smith PD, Cross DA, Politi K. (2020). Drug sensitivity and allele-specificity of first-line osimertinib resistance EGFR mutations. Cancer Research. 80(10): 2017-2030.
Published
Refereed?: Yes

33. Enfield K, Marshall E, Anderson C, Ng K, Rahmati S, Xu Z, Fuller M, Milne K, Rowbotham D, Becker-Santos D, English J, MacAulay C, Lam S, LOCKWOOD W, Chari R, Karsan A, Jurisica I, Lam W. (2019). Epithelial tumour suppressor ELF3 is a lineage-specific amplified oncogene in lung adenocarcinoma. Nature Communications. 10(1): 5438.
Published
Refereed?: Yes

34. Suzawa K, Offin M, Schoenfeld A, Plodkowski A, Odintsov I, Lu D, LOCKWOOD WW, Arcila ME, Drilon A, Yu HA, Riely GJ, Somwar R, Ladanyi, M. (2019). Acquired MET exon14 alteration drives resistance to EGFR-TKI in EGFR-Mutant Lung Cancers. Journal of Clinical Oncology - Precision Medicine. 3: 1-8.
Published
Refereed?: Yes

35. Ayeni D, Miller M, Kuhlmann A , Ho PC, Robles-Oteiza C, Gaefele M, Levy S, de Miguel FJ, Perry CJ, Guan T, Krystal G, LOCKWOOD WW, Zelterman D, Homer R, Liu Z, Kaech S, Politi K. (2019). Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFRmutant lung tumors. Cancer Immunology Research. 7(1): 172-198.
Published
Refereed?: Yes

36. Deng H, Liu H, De Silva T, Xue Z, Mohamud Y, Qu J, Zhang J, Jia W, LOCKWOOD WW*, Luo H* (*co-senior author). (2019). Coxsackievirus Type B3 is A Potent Oncolytic Virus Against KRAS-Mutant Lung Adenocarcinoma. Molecular Therapy - Oncolytics. 14: 266-278.
Published
Refereed?: Yes

37. Xue Y, Meehan B, Fu Z, Fiset P, Rieker R, Levins C, Kong T, Zhu X, Morin G, Skerritt L, Herpel E, Venneti S, Martinez D, Judkins A , Jung S, Camilleri-Broët S, Gonzalez A, Guiot MC, LOCKWOOD WW, Spicer J, Agaimy A, Rak J, Foulkes W, Huang S. (2019). SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer. Nature Communications. 10(1): 557.
Published
Refereed?: Yes

38. Lim JKM, Delaidelli A, Minaker SW, Zhang HF, Colovic M, Negri GL, von Karstedt S, LOCKWOOD WW, Schaffer P, Leprivier G, Sorensen PH. (2019). Cystine/glutamate antiporter xCT (SLC7A11) facilitates oncogenic RAS transformation by preserving intracellular redox balance. PNAS. 116(19): 9433-9442.
Published
Refereed?: Yes

39. Drilon A, Somwar R, Mangatt B, Edgren H, Desmeules P, Ruusulehto A, Smith R, Delasos L, Vojnic M, Plodkowski A, Sabari J, Ng K, Montecalvo J, Chang J, Tai H, LOCKWOOD W, Martinez V, Riely G, Rudin C, Kris M, Arcila M, Matheny C, Benayed R, Rekhtman N, Ladanyi M, Ganji G. (2018). Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers. Cancer Discovery. 8(6): 686-695.
Published
Refereed?: Yes

40. Suzawa K, Offin M, Lu D, Kurzatkowski C, Vojnic M, Smith R, Sabari J, Tai H, Mattar M, Khodos I, de Stanchina E, Rudin C, Kris M, Arcila M, LOCKWOOD W, Drilon A, Ladanyi M, Somwar R. (2018). Activation of KRAS mediates resistance to targeted therapy in MET exon14 mutant non-small cell lung cancer. Clinical Cancer Research. 25: 1248-1260.
Published
Refereed?: Yes

41. O'Farrell H, Harbourne B, Kurlawala Z, Inoue Y, Nagelberg A, Martinez V, Oh MH, Coe B, Thu K, Lam S, Lam W, Unni AM, Beverly L, LOCKWOOD WW. (2018). Integrative genomic analysis identifies GGA2 as a cooperative driver of EGFR mediated lung tumorigenesis. Journal of Thoracic Oncology. 14(4): 656-671.
Published
Refereed?: Yes

42. Unni AM, Harbourne B, Oh M, Wild S, Ferrarone JA, LOCKWOOD WW*, Varmus H* (*co-senior author). (2018). Hyperactivation of ERK by multiple mechanisms is toxic to RTK-RAS mutation-driven lung adenocarcinoma cells. eLife. 2018;7:e33718: 1-10.
Published
Refereed?: Yes

43. Halvorsen EC, Franks SE, Wadsworth BJ, Harbourne BT, Cederberg RA, Steer CA, Martinez-Gonzalez I, Calder J, LOCKWOOD WW and Bennewith KL. (2018). IL-33 increases ST2+ Tregs and promotes metastatic tumour growth in the lungs in an amphiregulin-dependent manner. Oncoimmunology. 8(2): e1527497.
Published
Refereed?: Yes

44. Halvorsen EC, Franks SEF, Wadsworth BJ, Steer CA, Martinez-Gonzalez I, Calder J, LOCKWOOD WW, Takei F, Bennewith KL. (2018). Amphiregulin is produced by ST2+ Tregs in response to IL-33 stimulation and promotes metastatictumour growth in the lungs. Oncoimmunology. 8(2): e1527497.
Published
Refereed?: Yes

Books

1. . (2021). Key Leaders' Opinion on Translational Lung Cancer Research. 1st edition: 195. Editors: Desheng Xiao, Chunlin Ou, Pier Luigi Filosso, WILLIAM W. LOCKWOOD.
Published, AME Publishing Company, Hong Kong

Conference Publications

1. Shi R, Farnsworth D, Atwal T, Chow J, Sheena R, Lee C-M, Inoue Y, Awrey S, McDonald P, Somwar R, Ladanyi M, Dedhar S, Bennewith K, LOCKWOOD W. Integrin-linked kinase facilitates drug tolerant persister cell survival and EMT in response to EGFR targeted therapy. 2024 IASLC World Conference on Lung Cancer, San Diego, United States of America
Conference Date: 2024/9
Abstract
2. Wang P, Ng R, Lam S, LOCKWOOD W. Active smoking induced gene expression discerns biological heterogeneity in lung adenocarcinoma patients who had formerly smoked. 2024 European Association of Cancer Research Annual Congress, Rotterdam, Netherlands
Conference Date: 2024/6
Abstract
3. Farnsworth DA, Ma LIJ, Macdougall E, Lu D, Naznin F, Shi R, Somwar R, Unni AM, LOCKWOOD WW. Potentiating ERK hyperactivation by targeting the proteostasis network. 2024 European Association of Cancer Research Annual Congress, Rotterdam, Netherlands
Conference Date: 2024/6
Abstract
4. Jajarmi JM, Nagelberg AL, LOCKWOOD WW. Identifying Modifiers of EGFR Induced Tumourigenesis to Develop New Therapeutic Strategies for Lung Cancer.2024 European Association of Cancer Research Annual Congress, Rotterdam, Netherlands
Conference Date: 2024/6
Abstract
5. Shi R, Farnsworth D, Atwal T, Chow J, Sheena R, Lee CM, Inoue Y, Awrey S, McDonald P, Dedhar S, Bennewith K, LOCKWOOD W. Integrin-linked kinase supports drug-tolerant-persister cell survival and EMT-mediated drug resistance by upregulating YAP during EGFR TKI treatment of lung adenocarcinoma. 2024 European Association of Cancer Research Annual Congress, Rotterdam, Netherlands
Conference Date: 2024/6
Abstract
6. Chuang, YC, Sihota, TS, Nagelberg, AL, and LOCKWOOD, WW. Exploring SNF2 Histone Linker PHD Ring Helicase (SHPRH)'s Role in Initiation and Development of Lung Adenocarcinoma. European Association for Cancer Research 2024 Congress, Rotterdam, Netherlands
Conference Date: 2024/6
Poster
7. Chuang, YC, Sihota, TS, Nagelberg, AL, and Lockwood, WW. The Role of SHPRH in Lung Adenocarcinoma Initiation and Development. BIG 24 Annual Research Conference, Vancouver, Canada
Conference Date: 2024/3
Poster

8. Sihota TS, Chuang YC, Nagelberg AL, Chow JLM, Shi R, and LOCKWOOD WW. Characterizing SHPRH as a Novel Tumour Suppressor Gene in Lung Adenocarcinoma. UBC Three Minute Thesis, Vancouver, Canada
   Conference Date: 2024/3
   Abstract
9. Chuang, YC, Sihota, TS, Nagelberg, AL, and Lockwood, WW. The Role of SHPRH in Lung Adenocarcinoma Initiation and Development. Life Science Symposium, Vancouver, Canada
   Conference Date: 2024/3
   Poster
10. Chuang, YC*, Sihota, TS, Nagelberg, AL, and LOCKWOOD, WW (Outstanding Speaker Award). The Role of SHPRH in Lung Adenocarcinoma Initiation and Development. IOP Tumour Signalling and Metabolism Workshop, Vancouver, Canada
    Conference Date: 2024/3
    Abstract
11. Chuang, YC, Sihota, TS, Nagelberg, AL, and LOCKWOOD, WW. Investigating SHPRH as a Risk Factor for Lung Adenocarcinoma Initiation and Development. Faculty of Medicine Building the Future, Vancouver, Canada
    Conference Date: 2024/3
    Poster
12. Shi R, Farnsworth D, Atwal T,Chow J, Inoue Y,Awrey S, McDonald P, Dedhar S, Bennewith KL, LOCKWOOD WW. Integrin-linked kinase epithelial-mesenchymal transition and osimertinib resistance in EGFR driven lung adenocarcinoma. Faculty of Medicine Research Day, Vancouver, Canada
    Conference Date: 2023/6
    Poster
13. Shi R, Farnsworth D, Atwal T, Chow J, Inoue Y, Awrey S, McDonald P, Dedhar S, Bennewith KL, LOCKWOOD WW. Integrin-linked kinase promotes epithelial-mesenchymal transition and osimertinib persistence/resistance in EGFR driven lung adenocarcinoma. Annual Congress of the European Association for Cancer Research, Turin, Italy
    Conference Date: 2023/6
    Poster
14. Shi R, Farnsworth D, Atwal T, Chow J, Inoue Y, Awrey S, McDonald P, Dedhar S, Bennewith KL, LOCKWOOD WW.Integrin-linked kinase mediates osimertinib tolerance and resistance by promoting epithelial-mesenchymal transition in EGFR-mutant lung adenocarcinoma. Keystone Symposia - The Resistant Tumor Microenvironment, Vancouver, Canada
    Conference Date: 2023/5
    Poster
15. Farnsworth D , Inoue Y, Johnson F, de Rappard-Yuswack G, Shi R, Lu D, Ma LIJ, Mattar MS, Ladanyi M, Somwar R, Unni AM, LOCKWOOD WW.MEK inhibitor resistance in lung adenocarcinoma is associated with addiction to sustained ERK suppression. Conference on Signaling in Normal Cells and Cancer Cells, Vancouver, Canada
    Conference Date: 2023/4
    Poster
16. Jajarmi JM *, Nagelberg AL, and LOCKWOOD WW. *poster award. Identifying Modifiers of EGFR Induced Tumourigenesis to Develop New Therapeutic Strategies for Lung Cancer. BIG Research Day 2023, Vancouver, Canada
    Conference Date: 2023/3
    Poster

17. Shi R, Farnsworth D, Atwal T, Chow J, Inoue Y, Awrey S, McDonald P, Dedhar S, Bennewith KL, LOCKWOOD WW. Integrin-linked kinase promotes osimertinib resistance by stimulating epithelial-mesenchymal transition in EGFR driven lung adenocarcinoma. 12th Annual UBC Bioinformatics, Interdisciplinary Oncology, Genome Science and Technology (BIG) Research Day, Vancouver, Canada
Conference Date: 2023/3
Poster

18. Sihota TS, Chuang YC, Nagelberg AL, Chow JLM, Shi R, and LOCKWOOD WW. Characterizing SHPRH as a Novel Tumour Suppressor Gene in Lung Adenocarcinoma. BIG Research Day 2023, Vancouver, Canada
Conference Date: 2023/3
Poster

19. Sihota TS, Chuang YC, Nagelberg AL, Chow JLM, Shi R, and LOCKWOOD WW. Characterizing SHPRH as a Novel Tumour Suppressor Gene in Lung Adenocarcinoma. Faculty of Medicine 2023 Building the Future- Research Trainee Day and Lecture Series, Vancouver, Canada
Conference Date: 2023/3
Poster

20. Shi R, Farnsworth D,Atwal T , Chow J, Inoue Y, Awrey S, McDonald P, Dedhar S, Bennewith KL, LOCKWOOD WW. Integrin-linked kinase is important for epithelial-mesenchymal transition and osimertinib resistance in EGFR driven lung adenocarcinoma. Faculty of Medicine Precision Health Symposium, Vancouver, Canada
Conference Date: 2023/2
Poster

21. Fraser D. Johnson, Sophie Jansen, Alvin Liu, Christina Brandst''adter, Daniel Lu, Amy Nagelberg, Dylan Farnsworth, Tianna Sihota, Jianghong An, Giovanni C Forcina, Anna Prudova, Jennifer Luu, Poul H.B. Sorensen, Harold Varmus, Romel Somwar, Scott J. Dixon, Steven J.M. Jones, Katja Becker, Gregg B. Morin, WILLIAM W. LOCKWOOD.Selectively targeting lung cancer with a novel small molecule that induces lethality through dual inhibition of disulfide reductases.Sixth AACR-IASLC International Joint Conference 2020, San Diego, United States of America
Conference Date: 2020/1
Poster
Refereed?: Yes

22. Inoue Y, LOCKWOOD WW. Activation of the RAS-ERK signaling suppresses neuroendocrine transcription factors and causes transdifferentiation of small cell lung cancer through modulation of histone modifications. BC Cancer Summit, Vancouver, Canada
Conference Date: 2019/11
Abstract

23. Johnson FD, Jansen S, Liu A, Brandstadter C, Lu D, Nagelberg A, Farnsworth D, Sihota T, Prudova A, Luu J, Sorensen PH, Varmus H, Somwar R, Becker K, Morin GB, LOCKWOOD WW.Inhibiting lung cancer by targeting disulfide reductase enzymes with a novel small molecule that induces reactive oxygen species. BC Cancer Summit 2019, Vancouver, Canada
Conference Date: 2019/11
Poster

24. Franks SE, Melese ES, Cederberg RA, Harbourne BT, Halvorsen EC, Shi R, Wadsworth BJ, Collier JC, Unni A, Oh MH, Lam V, Krysal G, Abraham N, Bennewith KL* LOCKWOOD WW* (Co-senior author). Reduction of oncogene-regulated CCL5 production in lung cancer cells leads to an altered immune microenvironment and decreased tumor burden in the lungs. BC Cancer Summit, Vancouver, Canada
Conference Date: 2019/11
Poster

25. Franks SE, Melese ES, Cederberg RA, Harbourne BT, Halvorsen EC, Shi R, Wadsworth BJ, Collier JC, Unni A, Oh MH, Lam V, Krysal G, Abraham N, Bennewith KL* LOCKWOOD WW* (Co-senior author). Reduction of oncogene-regulated CCL5 production in lung cancer cells leads to an altered immune microenvironment and decreased tumor burden in the lungs. BioCanRx Summit for Cancer Immunotherapy (Summit4CI), Victoria, Canada
Conference Date: 2019/10
Poster

26. Inoue Y, Somwar R, Ladanyi M, LOCKWOOD WW. Elucidating mechanisms of resistance to targeted therapies in mutant EGFR or KRAS driven lung adenocarcinoma harboring dual loss of p53 and RB1. 20th World Conference on Lung Cancer, Barcelona, Spain
Conference Date: 2019/9
Abstract
Refereed?: Yes

27. Franks SE, Melese ES, Cederberg RA, Harbourne BT, Halvorsen EC, Shi R, Wadsworth BJ, Collier JC, Unni A, Oh MH, Lam V, Krysal G, Abraham N, Bennewith KL*, Lockwood WW* (Co-senior author). Reduction of oncogene-regulated CCL5 production in lung cancer cells leads to an altered immune microenvironment and decreased tumor burden in the lungs. Cold Spring Harbor Laboratories Biology of Cancer: Microenvironment and Metastasis, Cold Spring Harbor, United States of America
Conference Date: 2019/9
Abstract
Refereed?: Yes

28. Franks SE, Melese ES, Cederberg RA, Harbourne BT, Halvorsen EC, Shi R, Wadsworth BJ, Collier JC, Unni A, Oh MH, Lam V, Krysal G, Abraham N, Bennewith KL* LOCKWOOD WW* (Co-senior author). Reduction of oncogene-regulated CCL5 production in lung cancer cells leads to an altered immune microenvironment and decreased tumor burden in the lungs. ImmunoBC 2019 Annual Meeting, Vancouver, Canada
Conference Date: 2019/6
Poster

29. Franks SE, Melese ES, Cederberg RA, Harbourne BT, Halvorsen EC, Shi R, Wadsworth BJ, Collier JC, Unni A, Oh MH, Lam V, Krysal G, Abraham N, Bennewith KL* LOCKWOOD WW* (Co-senior author). Reduction of oncogene-regulated CCL5 production in lung cancer cells leads to an altered immune microenvironment and decreased tumor burden in the lungs. BC Cancer Research Day, Vancouver, Canada
Conference Date: 2019/6
Poster

30. Lu D, Martinez V, Thu K, NISC Sequencing program, Lam S, Lam W, Varmus H, LOCKWOOD WW. Identification of the Hepatocyte Growth Factor Receptor as a Candidate Driver of Lung Adenocarcinoma. American Society for Human Genetics Annual Meeting, 2019, Vancouver, Canada
Conference Date: 2019/5
Abstract
Refereed?: Yes, Invited?: Yes

31. O'Farrell H, Oh MH, Harbourne B, LOCKWOOD WW. GGA2 as a candidate "Second-Hit" gene in lungadenocarcimona. Canadian Cancer Research Conference, Vancouver, Canada
Conference Date: 2019/5
Abstract, Invited?: Yes

32. Becker-Santos DD, Minatel BC, Thu KL, English JC, Martinez VD, MacAulay CE, LOCKWOOD WW, Lam S, Robinson WP, Jurisica I, Lam WL. Developmental transcription factor NFIB is a target of oncofetal miRNAs andis linked to tumour aggressiveness in lung adenocarcinoma. American Society for Human Genetics Annual Meeting, 2019, Vancouver, Canada
Conference Date: 2019/5
Abstract
Refereed?: Yes, Invited?: Yes

33. Luu, J. Johnson F, Bennewith K, LOCKWOOD W. Identifying secreted proteins that promote immune evasion during malignant lung transformation. ImmunoBC Anual Meeting 2019, Vancouver, Canada
Conference Date: 2019/5
Poster

34. Johnson F, Liu A, Lu D, Nagelberg A, Prudova A, Luu J, Inoue Y, Somwar R, Sorensen PH, Morin GB, LOCKWOOD WW. Using a novel small molecule inducer of oxidative stress to selectively target lung cancer cells. Bioinformatics, Interdisciplinary Oncology, and Genome Sciences and Technology (BIG) Research Day, Vancouver, Canada
Conference Date: 2019/3
Poster

35. Johnson F, Liu A, Lu D, Nagelberg A, Prudova A, Luu J, Inoue Y, Somwar R, Sorensen PH, Morin GB, LOCKWOOD WW. Thermal proteome profiling identifies glutathione disulfide reductase as a target of a novel small molecule that exploits a vulnerability to reactive oxygen species in lung cancer. Online Program book. European Proteomics Association (EuPA) 2019 Congress, Potsdam, Germany
Conference Date: 2019/3
Abstract

Presentations

1. (2023). Defining new biological vulnerabilities and therapeutic strategies for lung cancer patients. Princess Margaret Cancer Centre - University Health Network, Toronto, Ontario, Canada
Main Audience: Researcher
Invited?: Yes, Keynote?: No

2. (2023). Defining mechanisms of tumorigenesis and therapeutic response in lung adenocarcinomas driven by MET?ex14? mutations. MET in Cancer, Institute Pasteur Lille, Lille, France, France
Main Audience: Knowledge User
Invited?: Yes, Keynote?: No

3. (2021). Novel Systemic Treatment in NSCLC. World Conference on Lung Cancer, Singapore, Singapore
Main Audience: Researcher
Invited?: Yes, Keynote?: No

4. (2020). Mechanisms of small cell lineage transformation in resistance to targeted therapies. Plenary Session 10: Nongenetic Mechanisms of Resistance. Sixth AACR-IASLC International Joint Conference: Lung Cancer Translational Science from the Bench to the Clinic, San Diego, United States of America
Main Audience: Researcher
Invited?: Yes, Keynote?: No

5. (2019). SCLC Lineage Transformation in Lung Adenocarcinoma and Resistance to Targeted Therapies. Mini-Symposium on Lung Cancer Plasticity and Drug Resistance - World Conference on Lung Cancer, Barcelona, Spain
Main Audience: Researcher
Invited?: Yes, Keynote?: No

Knowledge and Technology Translation

2012/12

Scientific Officer and Grant Review, Standards Development
Activity Description: Peer review is the backbone of the scientific community and setting standards in the peer review process is of vital importance. I have sat on numerous national grant panels including: CCS Innovation Grant Biomarkers and Genomics Panel, both as a Reviewer and Scientific Officer; CIHR Cancer Biology and Therapy 2 Project Grant Panel; CRS Pharmacogenetics and Cancer Immunotherapy Operating Grant Panel. In addition, I have reviewed grants for international foundations including the Wellcome Trust, CRUK and French National Cancer Institute. Thus, I have had the opportunity to contribute to the development of these standards. In this capacity, I have been responsible for communicating the results of panel meetings - including the views of both scientists and community representatives - back to grant applicants. Thus, performing this task accurately is important in order to ensure that investigators receive information to better execute their studies.

2011/5

Outreach Facilitator, Citizen Engagement
Activity Description: Engaging the general public in scientific discourse is important. I have participated in events like the American Junior Academy of Science/AAAS– Breakfast with a Scientist (2011) to encourage bright young minds to pursue a career life science. Continuing in this pursuit, I was a panel member in the UBC 'Beyond the BSc' event, answering questions on careers in science (2016-2018). With directors at the BC Cancer Foundation (BCCF), I coordinated meetings with donors, taking them through tours of my lab and describing my research and its impact on patient care in Special Seminars. I also wrote the BCCF 'Partners in Discovery' blog to convey the impact of donations on cancer research in BC (2014-15). Recently, I founded Vancouver Underground Science which aims to engage the public through grassroots programs. Our first event was 'Beer with a Scientist' where we partnered with a local pub to host a talk/questions on 'Why haven't we cured cancer yet?', attended by >60 members of the public.

2006/11

Conference/Meeting Organizer, Research Uptake Strategies
Activity Description: Science is a collaborative effort. Large-scale studies require involvement of all members of the research community, from basic scientists to surgeons, pathologists and oncologists. I have a wealth of experience working in such teams, building new collaborations to achieve mutually desired goals. For example, I have organized and participated in institutional groups including the BCCA Lung Tumor, MSKCC Lung Program Project and NIH Thoracic Working Groups that have served as essential forums to present research and define strategies to improve patient care. In addition, I have played an important role in organizing meetings that define the direction of my field. For example, I have organized and contributed to the Mouse Models of Human Cancer Consortium Steering Committee meetings and I am currently on the Biology Track Planning Committee for the 2018 World Conference on Lung Cancer that attracts over 7,000 lung cancer researchers, clinicians and patient advocates from around the word.

2006/1 - 2016/12 Author - Journal Publications, Research Uptake Strategies
Activity Description: Dissemination of research findings with the scientific community is essential. I have consistently published my findings in scientific journals and presented at international conferences as part of this process. I have published 59 total publications (2006-present), 52 in refereed journals and 3 book chapters, with 4 additional papers currently in revision. Importantly, this includes 14 first, 8 second, 6 senior and 12 corresponding authorships, demonstrating my essential role in these projects. In total, these papers have 2849 total citations (H-index = 23, Google Scholar, 03/05/18) highlighting their impact on the field. Many of these papers were part of international collaborations, including a large initiative driven by the Canary Foundation for Early Cancer Detection (i.e. Cancer Cell 2011), a NIH Lung Cancer SPORE program lead by Dr. John Minna (ie. PLoS Medicine, 2010) and a NIH Program Project Grant led by Mark Kris at Sloan-Kettering (PNAS 2012, Cancer Discovery 2018).

2006/1 - 2016/12 Trainee Mentor - Scientific Outreach and Communication, Technology, Product, Process, Service Improvement/Development
Activity Description: Communication is an important part of science, for disseminating research findings and in acquiring funding. I have aimed to use my experience in this capacity to help trainees improve their science communication skills. This initially involved mentoring students in writing abstracts and presenting posters. This has proven beneficial as many of the trainees I have supervised have gone from presenting posters at local conferences to giving talks at international conferences. I have also been involved in the review of abstracts for the BC Cancer Conference and MMHCC Meetings and am co-coordinator of a class (Pathology 535 at UBC) that teaches graduate students the principles of scientific communication, from writing abstracts/grant proposals to giving talks. Recently, I was invited to be a mentor for the CCSRI/CIHR New PI Meeting that was part of the Canadian Cancer Conference in Montreal. Here, I was a panel member on a session for senior postdocs on how to negotiate a start-up package.

Student/Postdoctoral Supervision

Master's Thesis [n=6]

2024/9 Katie Sew, University of British Columboa
Principal Supervisor Thesis/Project Title: Characterizing the MET phophoproteome
Present Position: MSc Student - Lockwood Lab

2024/9 Asha Subramaniam, University of British Columboa
Principal Supervisor Thesis/Project Title: Developing DUSP inhibitors for lung cancer treatment
Present Position: MSc Student - Lockwood Lab

2023/9 Sarah Okun, University of British Columbia
Principal Supervisor Thesis/Project Title: *
Present Position: Graduate Student

2022/8 Jana Jajarmi, University of British Columbia
Principal Supervisor Thesis/Project Title: *
Present Position: Graduate Student

2022/6 Serena Chuang, University of British Columbia
Principal Supervisor Thesis/Project Title: *
Present Position: Graduate Student

2019/8 - 2023/4 Principal Supervisor	Tianna Sihota, University of British Columbia Thesis/Project Title: Developing agonistic therapeutic strategies for lung cancer based on synthetic lethal oncogene interactions Present Position: Graduate Student

Doctorate [n=3]

2022/9 - 2025/12 Principal Supervisor	Peiyao Wang, University of British Columboa Thesis/Project Title: Environment and lung cancer Present Position: MD/PhD Student - Lockwood Lab
2020/6 - 2025/12 Co-Supervisor	Rocky Shi, University of British Columbia Thesis/Project Title: Oncogene driven changes in the solid tumour microenvironment. Co-supervisor: Dr. Kevin Bennewith. Present Position: PhD student
2019/9 - 2025/12 Principal Supervisor	Dylan Farnsworth, University of British Columbia Thesis/Project Title: Investigating synthetic lethal interactions resulting from osimertinib resistance in lung cancer Present Position: PhD. Student, Lockwood Lab, BC Cancer

Post-doctorate [n=1]

2023/4 - 2025/12 Principal Supervisor	Farhana Naznin, University of British Columbia Thesis/Project Title: * Present Position: Postdoctoral Fellow